Rapamycin formulation offers hope for rare polyp disorder
Disease control
AVAILABLE
This expanded access program provides eRapa, an oral encapsulated form of rapamycin, to people with familial adenomatous polyposis (FAP) who have no good treatment options and cannot join a clinical trial. FAP causes hundreds of polyps in the colon and rectum, raising cancer risk…
Sponsor: Biodexa Pharmaceuticals • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC